Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Nuvation Bio Inc. stands seventh on our list among the best oncology stocks.

TheFly reported on January 12 that H.C. Wainwright reduced its price target on NUVB to $17 from $18 while maintaining a Buy rating. The firm said the company’s fourth-quarter Ibtrozi sales came in line with expectations.

On the same day, NUVB reported preliminary Q4 2025 net product revenue of approximately $15.7 million for IBTROZI (taletrectinib). The company also highlighted that 216 new patients started treatment with IBTROZI in the fourth quarter and received a $25 million milestone payment from Nippon Kayaku.

Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology patients. Its lead asset, IBTROZI (taletrectinib), targets rare and difficult-to-treat cancers. The company emphasizes precision medicine, pipeline expansion, and improving outcomes for patients with limited therapeutic options in oncology.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.